China SXT Pharmaceuticals (SXTC) Liabilities and Shareholders Equity (2018 - 2026)

China SXT Pharmaceuticals' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $34.8 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 60.43% year-over-year to $34.8 million; the TTM figure through Mar 2026 stood at $113.8 million (up 25.88% YoY), while the FY2026 annual figure was $34.8 million, up 60.43% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $34.8 million, up from $26.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $34.8 million in Q1 2026, with the low at $14.6 million in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $26.4 million (2025), against an average of $26.3 million.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity tumbled 34.23% in 2023, then jumped 112.49% in 2024.
• China SXT Pharmaceuticals' Liabilities and Shareholders Equity stood at $22.2 million in 2022, then sank by 34.23% to $14.6 million in 2023, then surged by 112.49% to $31.0 million in 2024, then slipped by 14.98% to $26.4 million in 2025, then jumped by 31.88% to $34.8 million in 2026.
• Business Quant data shows SXTC's Liabilities and Shareholders Equity at $34.8 million in Q1 2026, $26.4 million in Q3 2025, and $21.7 million in Q1 2025.